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Abstract
The search for druggable pockets on the surface of a protein is often performed on a single conformer, treated as a rigid
body. Transient druggable pockets may be missed in this approach. Here, we describe a methodology for systematic in silico
analysis of surface clefts across multiple conformers of the metastable protein a1-antitrypsin (A1AT). Pathological mutations
disturb the conformational landscape of A1AT, triggering polymerisation that leads to emphysema and hepatic cirrhosis.
Computational screens for small molecule inhibitors of polymerisation have generally focused on one major druggable site
visible in all crystal structures of native A1AT. In an alternative approach, we scan all surface clefts observed in crystal
structures of A1AT and in 100 computationally produced conformers, mimicking the native solution ensemble. We assess
the persistence, variability and druggability of these pockets. Finally, we employ molecular docking using publicly available
libraries of small molecules to explore scaffold preferences for each site. Our approach identifies a number of novel target
sites for drug design. In particular one transient site shows favourable characteristics for druggability due to high enclosure
and hydrophobicity. Hits against this and other druggable sites achieve docking scores corresponding to a Kd in the mM–nM
range, comparing favourably with a recently identified promising lead. Preliminary ThermoFluor studies support the
docking predictions. In conclusion, our strategy shows considerable promise compared with the conventional single
pocket/single conformer approach to in silico screening. Our best-scoring ligands warrant further experimental
investigation.
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Introduction
The desire to modulate protein function with small molecules
that can be administered as drugs has led to a plethora of studies
attempting to define and calculate the ‘‘druggability’’ of sites on a
protein [1,2,3,4,5]. Most studies have relied on experience from
inhibiting enzymes acting on small molecule substrates. Here the
target sites are well-formed surface pockets, characterized by high
curvature and low solvent accessibility. Recently ‘‘harder’’ targets
have been addressed. These include protein-protein interactions
and proteins belonging to large homologous superfamilies e.g.
kinases. In the former, the interfaces are larger and flatter [6]. In
the latter, inhibiting the common active site risks serious cross-class
side effects. Both these issues may be addressed by targeting clefts
that are not necessarily associated directly with the protein’s
biochemical function. The idea is that binding of small molecules
to such clefts may be more favourable and could still allosterically
modulate protein function, e.g. via preferential stabilization of a
particular state within the conformational landscape of the protein
in solution.
The search for suitable allosteric clefts requires consideration
of functional relevance and druggability. Functional relevance is
usually less obvious from structural snapshots for an allosteric site
than an active site. It may be deduced experimentally by
mutagenesis, or through observation of the binding site of known
ligands. Druggability has traditionally been indirectly assessed by
computational studies (docking) or in vitro screening. More
recently, quantitative predictors of cleft druggability have been
devised [2,3,5,7,8,9]. These commonly assess the size, shape,
buriedness and hydrophobic character of a site. However, a
major limitation is currently not addressed routinely: the
transient character of some clefts that may otherwise be of
interest in drug design. Druggable pockets on a protein’s surface
are most commonly assessed using a single 3D structure. This is
unsatisfactory because proteins undergo dynamic changes in
solution, sampling multiple conformations, each with potentially
different surface pockets. The existence of multiple conformers is
especially relevant to ligand recognition. Ligand binding inher-
ently tends to conformational selection [10,11], a process by
which protein-ligand interactions lower the free energy of a
conformer, increasing the stability and population of a state that
may otherwise rarely be observed. In recent years some notable
efforts have been made to identify transient sites. In the approach
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pioneered by Eyrisch and Helms [12], trajectory snapshots from
molecular dynamics simulations revealed transient pockets on the
surfaces involved in protein-protein interactions. In a more
recent study, the same authors showed that transient pockets
could also be revealed by methods that were more efficient
computationally than molecular dynamics, albeit usually at the
cost of reduced pocket diversity [13]. In another interesting
study, Schmidtke et al. [14] demonstrated how pocket tracking
across multiple structures with the program fpocket can highlight
important changes to a pocket, arising from both dynamics of a
single protein as well as evolutionary time in a family of
homologues. Recently, the importance of employing multiple
protein conformers in virtual screening has been highlighted
[15,16,17] and there is a growing trend for incorporating notions
of flexibility in the docking process. Despite these pioneering
studies, most current in silico screening starts with the selection of
a single pocket from a single conformer.
In this study we demonstrate how the approach of employing
multiple protein conformers at the selection-of-pocket stage can be
combined with predictions of druggability, to aid the identification
of transient, novel druggable pockets often missed in single
conformer approaches. Our study focuses upon a1-antitrypsin
(A1AT), the archetypal member of the serpin (serine protease
inhibitor) superfamily [18]. Its characteristic native fold (Figure 1)
is metastable and this is key to its antiprotease function [19]. It is
an excellent candidate to assess our strategy for a number of
reasons. Firstly, A1AT is a medically important target. Its
metastability is subverted by pathogenic mutations that cause
A1AT to polymerise. This causes diseases of the liver (neonatal
hepatitis, cirrhosis and hepatocellular carcinoma) and lung (early-
onset emphysema) through loss- and gain-of-function mechanisms
[20]. Secondly, the biological function and dysfunction of serpins
is coupled to marked conformational changes involving large
rearrangements of their structure [21]. Moreover, extensive
mutagenesis experiments demonstrate that mutations around
surface clefts can significantly alter the stability of native A1AT
[22]. Metastability is therefore related to pocket vacancy,
indicating that ligand binding in a range of allosteric sites may
modulate stability, and hence, pathological conformational
change. Lastly, a range of high-resolution crystallographic datasets
are available for wild type and mutant A1AT species in native,
metastable (or stressed ‘S’) and relaxed (‘R’), hyperstable states,
allowing comparison of computationally derived conformers with
structural data. Following docking studies we have gone on to
assess some of our most promising findings experimentally,
identifying small molecule ligands with potential for development
as novel therapeutics.
Results
Identification of Surface Pockets Present in Crystal
Structures of a1-antitrypsin
We denote the eight top-ranking surface clefts identified by
SiteMap [2] on the structure of native A1AT (PDB entry: 1qlp) A
to H (Figure 2). Sites A, D and G are each clearly distinct from
other cavities, whereas sites C, B and E, as well as F and H are
very close in space. The B, D and G sites are all defined by loop
regions. In the case of site B, the loop involved is the reactive
centre loop (RCL). It is also interesting to note that sites C and E
are proximal to the glycosylation site Asn247, whereas D is
proximal to glycosylation site Asn46. The largest predicted site on
the native wild type A1AT (1qlp) is site A, adjacent to strand 2 of
b-sheet A. This site scores the highest for tight binding of drug-like
ligands with SiteMap scores (SiteScore 1.03, Dscore 1.03) highly
Figure 1. The structure of the wild type a1-antitrypsin. Front (A) and back (B) views of the structure of A1AT in cartoon representation (PDB
entry: 1qlp). The secondary elements are coloured as follows. ß-sheets: A (red), B (blue), and C (yellow); helices: A (cyan), B (apricot), C (blue), D (grey-
green), E (purple), F (yellow), G (orange), H (pink), I (olive); loops: reactive centre loop (RCL, red), all other loops (green).
doi:10.1371/journal.pone.0036612.g001
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consistent with those observed in sites binding drugs with a
submicromolar Kd (mean 1.01) [2].
Having identified potentially interesting sites on a single crystal
structure, we assessed how persistent these sites were across our
dataset of different crystal structures of A1AT (Table 1 and
Figure 3A). In structures containing the metastabilizing mutation
Ala70Gly (PDB entries: 1hp7, 1oph and 1iz2), we identified an
additional site (here referred to as site ‘‘I’’), located between the H-
helix, the s4-s6 of the B ß-sheet and the A-helix. This site is small
(45 A˚3), and very hydrophobic (the ratio of hydrophobic to
hydrophilic character measured by SiteMap’s ‘‘balance’’ property
is 5.1, with 1.6 being the average balance for tight-binding sites
[2]). Despite the small size of this site, the corresponding Site- and
Dscores (0.92 and 0.92 respectively) calculated by SiteMap
indicate a promising pocket for targeting with small molecule
drug-like ligands. Although site I is present as a cavity in the
remaining non-mutated structures, it is not solvent-accessible, and
so is not identified by SiteMap. Interestingly, in PDB entry 1hp7,
sites E and I are combined by SiteMap into one site, indicating
that a ligand could possibly straddle both. Of the remaining eight
sites, four are present in both the stressed and relaxed forms of
A1AT (C, D, E, F), and four are only found in the stressed form
(A, B, G and H). We summarise our results for the properties of
each site in Figure 3.
A large variation is observed in the volumes of all the larger sites
among the eight crystal structures studied reflecting significant
conformational changes across this dataset. However, even the
largest of these sites (1qlp, site A: 234 A˚3) is small compared with
the average volume of drug-binding sites (reported as 600 to 900
A˚3, depending on the method used to measure them [23]).
Nevertheless, six of the sites (A, B, C, D, E and I) have a median
SiteScore higher than 0.8, the recommended value for distin-
guishing drug-binding from non-drug binding sites [2]. Sites A, C,
and E demonstrate SiteScores .1.01, consistent with submicro-
molar drug-binding, in at least one crystal structure [2].
Incidence and Variability of Surface Pockets within a
Computationally-generated Conformer Ensemble
An ensemble of 100 A1AT conformations was generated from
the native wild type structure 1qlp using the distance constraints-
based method within CONCOORD [24] (Figure S1). SiteMap
was then used to assess pockets A–I across the entire computa-
tionally generated native-like ensemble. The frequency of occur-
rence of each site across all conformers is summarised in Figure 3B.
The boxplots in Figures 3C–F summarise selected SiteMap
property results for these sites. Similar trends for the volumes
and site scores are observed for conformations produced using
more extensive sampling, or a different structure of native wild
type A1AT (2qug) as the starting point for the CONCOORD
simulation (data not shown). The majority of the values for the
Site- and DScores (Figures 3C and 3D respectively), volume
(Figure 3E), and hydrophobic/philic balance (Figure 3F) for
pockets in the crystal structures are within the boxplot limits. Thus
the A1AT cavity characteristics explored by the computational
conformers are supported by crystallographic observations. In
addition, more detailed assessment of the computational conform-
ers demonstrating the maximum Dscore for each cavity using the
PROSESS server [25] indicated they were of comparable quality
to experimental structures in our dataset in terms of geometry and
packing (Table S1).
The behaviour of the A site across the computationally
generated conformeric ensemble demonstrates the conservative
nature of the conformational lability simulated by the program
CONCOORD. Within the dataset of crystal structures of native
A1AT the A site is largest and most druggable in 1qlp, the starting
template for our CONCOORD simulation. The site is retained in
96% of the generated ensemble (Figure 3B) and displays higher
volumes (Figure 3E) and druggability scores (Figures 3C & D)
across these conformers than observed across the crystallographic
structures. Despite this conservative approach, the ensemble
generated by CONCOORD demonstrates that even these small
fluctuations can have major consequences for surface clefts in
A1AT, simulating pocket ‘‘breathing’’ in solution. Thus pocket
volumes varied#3-fold for many sites (Figure 3E) and druggability
scores showed up to 2-fold variation (Figure 3D). For many sites a
source of high variability was their merging with other sites via
formation of a channel of interconnected subsites. In particular, a
channel ran from the RCL to the H-helix incorporating sites B, C,
E and I in various combinations across several conformers (Figure
S2).
A number of other sites have the potential to achieve
druggability scores comparable to site A within the ensemble.
However, the spread of scores across the conformational ensemble
(Figure 3C) indicates that the ligand-favouring properties of these
sites are subject to greater fluctuation than the A site. Only three
sites (F, G and H) have median SiteScores below the 0.8
Figure 2. The nine top-ranking surface pockets identified by
SiteMap on a1-antitrypsin. Coloured spheres represent the SiteMap
predictions for eight top-ranking surface clefts on the wild type a1-
antitrypsin (PDB entry 1qlp, in grey cartoon representation): site A:
green, B: cyan, C: blue, D: purple, E: fuchsia, F: orange, G: slate blue, H:
brown. The yellow spheres correspond to the ninth site, I, a cleft
identified on crystal structures of A1AT containing the Ala70Gly
mutation.
doi:10.1371/journal.pone.0036612.g002
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recommended cut-off for promising drug targets. In general, the
SiteScore for a pocket correlates with the volume of that pocket,
but it is interesting that site I, although relatively small, scores very
highly (its median druggability score is highest after site A, among
sites not defined by the RCL). This is probably due to its strongly
hydrophobic environment (see Figure 3F), which has highly
favourable drug binding characteristics.
Surface Cleft Variability Assessed by Provar
To assess the variability of each predicted site in terms of the
residues that line the site we employed Provar [26] a method
recently developed in our group for the calculation and depiction
of surface cleft variability. Provar uses an ensemble of conformers
and their predicted pockets as input, calculates the propensity of
each residue to line a pocket, and aids visualization by mapping
the results on a single conformer structure. Provar results for the
100 CONCOORD conformers of A1AT are summarized in
Figure 4. The Provar analysis is consistent with SiteMap analysis
data (Figure 3B), and provides additional information about which
residues are consistently part of a pocket and which are only
occasionally so. For example, the majority of the residues lining
the A pocket appear to be persistently part of a cleft across the
CONCOORD conformer ensemble (Figure 4C). By contrast, of
the residues surrounding the I pocket, only three are consistently
pocket-lining: Leu276, Ile375 and Lys380 (Figure 4D). As the I
pocket is only identified in about a quarter of all conformers, these
residues must be often part of a different pocket that incorporates
part of the I site. Moreover, Provar offers an insight into how
conformational changes affect a pocket: pockets that have many of
their residues coloured red (e.g. site A, Figure 4C) are likely to be
changing in volume (as evidenced also in Figure 3) by ‘‘breathing’’-
style motions that inflate and deflate the site without having much
effect on which residues are pocket-lining. Sites that have many
residues surrounding them coloured pink (e.g. site I) are either
transiently observed, or change shape and volume by burying and
exposing different parts of the site in different conformers. Such
sites are consequently more likely to be missed by software that
identifies pockets, if only one conformation or poor sampling of
conformers is used.
Global Fragment and DrugBank Library Docking Studies
To further characterize the A–I pockets we proceeded to dock a
set of representative fragments from the ZINC database and
compounds from the DrugBank library to each of the sites on
A1AT using Glide. Our in silico fragment screen identified high-
scoring fragments for each site, highlighting chemotypes that may
be used as starting points for future in vitro exploration. The ZINC
identification codes for the 5 top-scoring fragments against each
site are provided in Table S2. The docked poses of these fragments
can be used to define pharmacophores for each site. Encourag-
ingly, the top scoring fragments for the A site clustered in the area
identified in our previous proof-of-principle study as a target for
pharmacophores capable of blocking polymerization of A1AT
while preserving inhibitory function (Figure 5). The area of the
pharmacophore is defined by Asn104, Thr114 and His139, and
several of our fragment poses favour hydrogen bonds to the
threonine and histidine residues.
The protein-fragment interactions within the other, less well
characterized, sites provide great insight into the ligand-binding
capabilities of these pockets. For example, the top 10 fragments in
the I site have at least one hydrogen bond to one of three residues:
Thr273 (side-chain oxygen OG1 acts as an acceptor to 5 ligands),
Lys380 (backbone oxygen O acts as donor to 7 ligands) and
His269 (ND1 acts as donor to 4 ligands). Moreover two areas
within the site are often occupied by hydrophobic rings. These
findings can be used to build a pharmacophore template for
further searches of additional ligand databases.
Overall the sites identified by SiteMap analysis demonstrated
specificity even when probed with small fragment compounds, that
are intrinsically more likely than larger compounds to bind
promiscuously [27]. Top-scoring fragments for each site typically
scored better for binding at that site than against any other site
(Figure S3).
Our second docking experiment scanned all pockets with the
DrugBank collection of small molecules in an effort to identify any
high-ranking ligands that are already used, or being tested as
drugs for different targets. 12,115 small molecule ligand structures
based on 5,897 molecules from the DrugBank library were docked
using Glide (see Methods for details) to each of the nine surface
clefts A–I. Docking scores for each ligand successfully docked to
each site are summarized in Figure 6. In these plots we have
merged the distribution of docking scores for sites B, C and E
(labelled as site BCE), as well as F and H (FH), as the necessity of
using a reasonable-size receptor grid in docking means that we
cannot exclude ligands from docking to neighbouring sites, even if
the grid is centred on a specific site. As is usual for docking
calculations, the majority of the ligands interacted in silico with
relatively poor predicted binding energies (23 to 25 kcal/mol),
Table 1. The dataset of selected crystal structures of A1AT used in this study.
Description PDB id Resolution (A˚) Mutations
Stressed – Native wild type 1qlp [30] 2.00 None
Stressed – Native wild type 2qug [41] 2.00 None
Stressed – Native with citrate bound 3cwm [41] 2.51 None
Stressed – Native mutant 1hp7 [42] 2.10 Ala70Gly
Stressed – Native mutant 3drm [32] 2.20 Thr114Phe
Stressed – Native mutant 1oph [43] 2.30 Ph351Leu, Thr59Ala, Thr68Ala, Ala70Gly,
Cys232Ser, Met358Arg, Met374Ile, Ser381Ala,
Lys387Arg
Relaxed – Uncleaved RCL (kinetic trap) 1iz2 [37] 2.20 Phe51Leu, Thr59Ala, Thr68Ala, Ala70Gly,
Arg101His, Val364Ala, Met374Ile, Glu376Asp,
Ser381Ala, Lys387Arg
Relaxed – Cleaved reactive loop 1ezx [19] 2.60 None
doi:10.1371/journal.pone.0036612.t001
Assessment of Druggable Pockets on a1-Antitrypsin
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36612
Figure 3. Properties of surface pockets in crystal structures and in silico conformers of a1-antitrypsin. Persistence of clefts A–I among
A1AT crystal structures (A) and computationally produced conformers (B). Where the sites C and E overlapped, the data are presented under the label
‘‘C_E’’. The distribution of SiteMap calculated properties for the 100 in silico conformers are shown as boxplots: SiteScore (C), DScore (D), site volume
Assessment of Druggable Pockets on a1-Antitrypsin
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indicating poor potential for drug development. However,
promisingly, low energy outliers in these distributions achieve
scores in the range of27.5 to28.8 kcal/mol for each site (Table 2
and Figure 7). These scores are comparable to the score of
compound ‘‘CG’’, a molecule identified in a previous study as an
inhibitor of A1AT polymerization (CG achieves a score of
28.7 kcal/mol against its target site (A) after induced fit docking
using Glide). Moreover, the best-scoring ligand for each site
appeared highly selective for that site (Figure 6B). The best overall
scores were achieved for sites BCE and FH. The highest-scoring
ligand interaction was for 7,8-dihydro-7,7-dimethyl-6-hydroxyp-
terin (DrugBank ID DB02278). Despite the relatively small size
(209 Da) of this ligand, it achieved a score of 28.8 kcal/mol
against the BCE site. However in our simulations, this molecule
bound the RCL with likely adverse effects on the enzyme
inhibitory function of A1AT.
Since larger compounds (.350 Da) are considered unfavour-
able as leads for drug design we also considered the 10 best
performing ligands in terms of their ligand efficiency for each
site. Ligand efficiency is traditionally defined as the docking
score divided by the number of heavy atoms, but here we are
referring to the natural logarithm scaling of the ligand
efficiency, a metric that the Schro¨dinger developers suggest
gives a better fit to experimental data. Within these best ligand
efficiency sets we then selected the ligand with the best overall
docking score to avoid overcompensating for size at the expense
of docking score. Some of these (‘best-efficient’) ligands
conserved interactions that are important in the binding of
the highest scoring ligand overall (‘best-overall’). Thus, within
the I site, hydrogen bonding of a charged amine group to the
backbone of Ser140 was seen with both the best-efficient
(DrugBank ID: DB00610) and best-overall (DB07124) ligands.
Similarly the aromatic ring of the most efficient ligand for the I
(E) and hydrophobic vs. hydrophilic character balance (F). The corresponding data for crystal structures are shown as red symbols superimposed on
the boxplots; 1qlp (circle), 2qug (plus sign), 3cwm (square), 1hp7 (diamond), 3drm (triangle point up), 1oph (triangle point down). Data are shown
only for sites identified within PDB entries for native (stressed, ‘S’) forms of A1AT, as these are likely to be the appropriate target states for the design
of polymerization inhibitors.
doi:10.1371/journal.pone.0036612.g003
Figure 4. The pocket-lining propensity of the residues of a1-antitrypsin calculated with Provar. Ribbon representation of A1AT (front, A
and back, B) coloured by the residue-based Provar probabilities. Provar colours each protein residue according to its probability of being pocket-
lining in an ensemble of conformers (here, 100 CONCOORD-produced conformations of A1AT). The first (0.05) and third quartile (0.92) of the
probability distribution are used as the white and red limits of the spectrum respectively. Hence, residues appearing red belong to the top quartile
distribution, i.e., in this case, they are pocket-lining in more than 92% of the conformers. (C) and (D): The SiteMap predictions for two pockets (A and I
respectively) are shown as solid spheres, and every residue with an atom within 3.75 A˚ of any sphere is shown in stick representation coloured by its
Provar value. Depth-cueing has been switched off in these figures to preserve the variation in the colouring of the residues.
doi:10.1371/journal.pone.0036612.g004
Assessment of Druggable Pockets on a1-Antitrypsin
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36612
site (DB03329) overlaps with the positions of all other aromatic
rings in the top 10 scoring ligands.
Induced Fit Screening for Promising I Site Ligands
For a flexible protein, like A1AT, rigid receptor docking is likely
to miss many ligands that require small structural rearrangements
in order to fit some of the smaller sites. In this case, docking
calculations that allow for induced fit are recommended. We
experimented with the induced fit protocol mostly with the I site,
as this is the smallest of all and more likely to benefit from such a
protocol, whereby ligands are docked into sites in a soft mode
(repulsive forces are very much reduced), then the protein and the
ligand are allowed to relax, and finally the ligand is redocked to
the relaxed conformer of the receptor. We found that the induced
fit docking protocol dramatically changes the results for some
ligands.
We illustrate two examples here of two natural compounds with
promising results. Menthol (DB000825) is a natural compound of
mint oils that scores reasonably well (26.6 kcal/mol) in the
original docking trial (with the receptor kept rigid) and, more
importantly, ranks eighth out of the 10,000 reported ligand poses.
Following induced fit docking, this score improves dramatically to
28.5 kcal/mol, aided by a small rearrangement of His269, which
results in an additional hydrogen bond to the ligand. Thymol is
another interesting hit against site I. In preliminary docking
experiments (without prior protein refinement in Glide) we
observed that thymol was the fourth best scoring molecule against
this site. Thymol is a natural product of thyme and a known
protein binder [28] that is used as a stabilizer in pharmaceuticals
as well as an antiseptic, vermifuge, antibiotic and fungicide, so it
may be an interesting ligand to explore. Unlike many of the larger
ligands that were found bound mostly on the outside of the cavity,
thymol docked inside and showed a good complementarity to the
site. Following protein refinement (a recommended procedure in
Glide), thymol could not be docked inside the I site, resulting in a
very poor docking score (Figure 8A). However, after induced fit
docking thymol could enter the cavity and achieved a Glide score
of 28.3 kcal/mol (Figure 8B). Finally, a series of molecules
comprising the thymol scaffold resulted in several good hits, the
top-scoring one being 5-ethyl-2-(4-ethyl-2-hydroxy-phenyl)phenol
(PubChem CID: 19850961), which binds the I site with an
impressive score of 210 kcal/mol. This score is equivalent to a Kd
prediction in the nanomolar range (Figure 8C).
Figure 5. Fragment docking to the A site targets the
pharmacophore defined by Asn104, Thr114, and His139. Best
poses of the top-scoring 20 fragments (coloured sticks) from the ZINC
dataset docked in the A site of A1AT (cartoon, blue). The majority of
these fragments fill the pocket defined by Thr114 and Asn104 at the
top, and His139 at the bottom (thin sticks, cyan), identified in our
previous study as a potential allosteric site for targeting A1AT
polymerization. Some of the fragments take advantage of hydrogen
bonding opportunities presented by His139 and Thr114.
doi:10.1371/journal.pone.0036612.g005
Figure 6. Results from docking the DrugBank collection against nine pockets on a1-antitrypsin. (A) Boxplot distributions of docking
scores for DrugBank molecules docked to each of the nine sites A to I. Only the top-ranking pose is included for each ligand and only ligands of
molecular weight less than 500 Daltons are included in this plot. (B) The best-scoring ligand for each site is assigned a worse score when docked
against each of the other sites. The red diamonds represent the best docking score for each ligand depicted in Table 2, when docked to the site
where it is ranked top. The black diamonds correspond to the scores for each of these ligands when docked to all other sites. The x-axis labels
correspond to the DrugBank ID of the ligand and, in brackets, the site against which it is selected as ‘‘best-scoring’’, e.g. 07124(A) refers to DrugBank
entry DB07124 which achieves its best score against site A.
doi:10.1371/journal.pone.0036612.g006
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Another interesting observation relating to the I site is that
there seems to be a transient hydrophobic pocket next to the
originally identified pocket, which, in some conformers, is
merged with that site. This can allow larger ligands with two
rings connected by a flexible linker to dock in a way that takes
advantage of both hydrophobic patches. For example, when
docking DrugBank entry DB07263 using the induced fit
protocol, we can obtain the pose depicted in Figure 8D where
two of the aromatic rings are placed in the two hydrophobic
subpockets making up the site in this conformer (yellow surfaces
in Figure 8D). This pose achieves a very respectable Glide score
of 29.5 kcal/mol. As this particular ligand does not take full
advantage of the hydrogen bonding opportunities clearly
depicted in the SiteMap surfaces of the site (Figure 8D surfaces
in blue and red), we can assume that the affinity could be further
improved by adding suitable functional groups that could interact
with polar residues on the receptor.
ThermoFluor Experiments Validate Interactions Predicted
in silico
A small number ofhits fromour docking studies wereassayed using
thermal shift experiments (ThermoFluor). All compounds selected
for testing had shown promising docking scores either using the
induced fit protocol, or in preliminary docking studies using rigid
receptor docking. Table 3 summarises the results for the three of the
eight ligands tested that demonstrated significant thermal shifts (4-
nitrocatechol, 2,6-diisopropylphenol and thymol), compared with
the control substance (DMSO). The corresponding ThermoFluor
graphs for these three ligandscanbe found inFigureS4; theyshowthe
differencebetweentheassayedmeltingtemperatureof theincubation
with compound and the average melting temperature of an
appropriate A1AT control incubated under the same conditions (in
this case, DMSO concentration). One of the eight compounds
assayed (4-nitrocatechol, predicted to bind at the I site) demonstrated
an average thermal shift exceeding 1uC. Interestingly, two of the
compounds representing hits to the I site (thymol, and 2,6-
diisopropylphenol) appeared to destabilise the protein, causing a
negative shift in the melting temperature, which was particularly
pronounced for thymol (average of 21.66uC). Negative shifts may
alsobeduetothehydrophobicnatureof thecompounds,whichunder
the assay conditions may induce non-specific destabilization of the
folded state [29]. Whether stabilizing or destabilizing, the observed
shifts in the melting temperature ofA1ATsupport our dockingresults
and indicate that the compounds assayed are most likely interacting
with our protein.
Discussion
Transiently druggable pockets on the surface of proteins can be
missed by in silico screens to identify the most promising target site
on a protein, commonly based upon a single structural snapshot.
Such pockets are of particular interest in cases where the protein
target undergoes large conformational variations, as in the
archetypal serpin A1AT. Here, we present an alternative
methodology that characterizes more pockets, and simulates their
solution behaviour in greater detail than a single conformer/single
pocket approach.
In this study we focused our efforts on identifying druggable
pockets on the surface of native A1AT that could be the targets of
inhibitors blocking polymerization. Previous in silico attempts to
identify small molecules that can act as inhibitors of polymerisa-
tion have concentrated on what we refer to in this paper as the A
site, a large cavity between the ß-sheet A and the D-helix [30].
This site was seen as a good drug target, as the space filling
Thr114Phe mutation situated in the A site reduces polymerisation
and preserves inhibitory function of native wild type A1AT in vitro,
and increases secretion in a mammalian cell model of disease
[31,32]. Drug design studies based on the Thr114Phe mutant and
in silico research focusing on this site have led to ligands that
blocked polymerisation of A1AT in vitro [33]. However, they did so
irreversibly and with the undesirable side effect of blocking the
inhibitory action of A1AT [32,34]. Hence, there is both scope and
need for targeting alternative sites on A1AT. A recent attempt at
identifying such sites across a range of serpins has revealed at least
one site where selected sugars and amino acid derivatives may
bind, acting as chemical chaperones that reduce polymerization
[35]. The aim of the study described here was to identify
potentially druggable sites on A1AT that have not yet been
targeted in in silico screens.
We expected to see clues of the existence of alternative
potentially druggable sites in the available crystal structures of
A1AT. Indeed, crystal structures of A1AT allow us a glimpse of
the variety of conformations sampled by this protein. This
inherent flexibility, intimately linked to function, is dispersed
across the whole protein [22,36,37,38,39] and thus potentially
reflected in the properties of pockets on the surface. Analysis of
available crystal structures revealed considerable variability in the
surface clefts between different conformers, and suggested that this
variability should not be ignored in structure-based drug design.
We showed that probing deeper into the variability of potential
druggable pockets could be done with a relatively cheap,
constraints-based computer simulation that efficiently explores
part of the protein conformational space. Additionally, we
Table 2. The best-scoring and ‘‘best-efficient’’ small molecules from DrugBank docked against each of the sites A-I on A1AT.
Best overall docking score Best scoring within ten most efficient
Site DrugBank ID
Glide SP score
(kcal/mol)
Molecular Weight
(Daltons) DrugBank ID
Glide SP score
(kcal/mol)
Molecular Weight
(Daltons)
A DB07124 28.3 384.4 DB00610 27.9 167.2
B/C/E DB02278 28.8 209.2 Same as best overall
D DB04861 27.9 405.4 DB02377 27.2 150.1
F/H DB08003 28.3 486.5 DB00529 26.8 126.0
G DB07597 27.9 163.2 Same as best overall
I DB03536 27.5 379.4 DB03329 26.2 111.2
Diagrams, IUPAC names and PubChem CIDs for all DrugBank entries in this table can be found in Figure 7.
doi:10.1371/journal.pone.0036612.t002
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demonstrated that this approach can lead to identification of both
novel (transient) sites, and also pre-existing pockets deemed non-
druggable in a single crystal structure, that may demonstrate
substantial druggability in the solution ensemble. Identification of
such sites is the first step towards a structure-based drug design
strategy that would seek to stabilize conformations where these
sites are present and druggable. Such an approach may be
particularly fruitful in proteins like A1AT, where the design of
small molecule modulators has to strike a delicate balance between
stabilizing the stressed state in order to reduce the protein’s
tendency to polymerise, and preserving the protein’s antiprotease
function.
The variability of each pocket was further probed using Provar,
a method recently developed in our lab. Provar allows us to
highlight and readily visualize residues responsible for the
variability of a protein pocket across an ensemble of conformers.
This information allows us an insight into the origin of the pocket
variability and can assist in silico induced-fit type screening within
high throughput studies, where keeping the number of residues
that are allowed flexibility small is necessarily limited. We believe
the combination of druggability and variability predictions could
be very interesting for many proteins that are difficult targets due
to their flexibility. We are currently pursuing an automated
combination of these predictions in our laboratory.
The conformers in which each pocket achieved its highest
druggability score were selected for docking studies, employing the
publicly available database of marketed and experimental drugs
DrugBank. These docking experiments highlighted several low
molecular weight ligands that scored well on individual sites and
were specific for these sites. Promisingly, several of the docking
scores of our best-scoring ligands at the novel targets are
comparable to the docking score of compound ‘‘CG’’, a molecule
previously identified as an inhibitor of A1AT polymerization
in vitro and in mammalian cells [34].
Our approach has also revealed sites that could become the
focus of future in vitro studies. A small but very hydrophobic site
Figure 7. Top-scoring DrugBank molecules against the a1-antitrypsin sites. IUPAC names and PubChem CIDs for the DrugBank IDs in
Figure 6 and Table 2 are: DB07124: 3-[(2S)-2-amino-3-[(5-{7H-pyrazolo[3,4-c]pyridin-5-yl}pyridin-3-yl)oxy]propyl]-6H-indole, PubChem CID: 46937052;
DB00610: 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol, PubChem CID: 5906 DB02278: 2-amino-6-hydroxy-7,7-dimethyl-3,4,7,8-tetrahydropteridin-4-
one, PubChem CID: 3340355; DB04861: 1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydro-
xyethyl]amino}ethan-1-ol, PubChem CID: 71301; DB02377: 2-aminopurin-6-one, PubChem CID: 764; DB08003: (2S)-2-acetamido-N-[(2S)-1-amino-1-
oxo-3-[4-[(5S)-1,1,3-trioxo-1, 2-thiazolidin-5-yl]phenyl]propan-2-yl]-3-phenylpropanamide, PubChem CID: 9547915; DB00529: phosphonoformic acid,
PubChem CID: 3415; DB07597: (1R,2S)-2-amino-1,2,3,4-tetrahydronaphthalen-1-ol, PubChem CID: 6420129; DB03536: benzyl N-[(1S)-4-[(diamino-
methyl)amino]-1-{[(2S)-3-oxobutan-2-yl]carbamoyl}butyl]carbamate, PubChem CID: 6398520; DB03329: pyridine-2-thiol, PubChem CID: 2723698.
doi:10.1371/journal.pone.0036612.g007
Figure 8. Induced fit docking allows the discovery of high affinity hits for site I. (A) Thymol (DrugBank ID DB02513, in wire representation)
docks on the outside of the main cavity of the I site (small white spheres) and does not reach the hydrophobic pocket within the cavity (yellow
surface), resulting in a poor docking score (23.2 kcal/mol). (B) After induced fit docking, thymol (in stick representation) enters the site, which now
comprises a larger hydrophobic cavity; the docking score is consequently greatly improved to 27.8 kcal/mol. The initial docked pose of thymol
before the application of IFD is shown superimposed in wire format. (C) A derivative of thymol, 5-ethyl-2-(4-ethyl-2-hydroxyphenyl)phenol, (PubChem
CID 19850961, sticks coloured by element) achieves an impressive score of 210 kcal/mol after induced fit docking, whilst retaining the original
thymol pose (in blue) for the substructure that is common to both molecules. (D) Best-ranking pose for DrugBank ID DB07263 ([{2-bromo-4-[(2R)-3-
oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid, in stick representation) following induced fit docking. In this protein conformer, the
channel connecting sites I and C has been opened creating two hydrophobic subpockets (predicted by SiteMap and depicted here in yellow semi-
transparent surface). Two of the aromatic rings of this ligand are placed in these subpockets. This ligand achieves a very good docking score
(29.5 kcal/mol), despite the fact that several hydrogen bonding opportunities (depicted by the blue and red surfaces, corresponding to H-bond
donor and acceptor, respectively) are not satisfied in the case of this ligand.
doi:10.1371/journal.pone.0036612.g008
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(site I) that is present in about one fifth of our in silico-produced
conformers was initially identified by SiteMap in three crystal
structures, carrying the Ala70Gly mutation. This mutation is
known to increase the stability of the stressed state, oppose the
propensity to polymerisation and retain the functionality of the
protein, while inducing widespread changes in cavity sizes within
A1AT. Further analysis showed that this site is present in all other
crystallographic structures but it is not solvent accessible. Crucially
it became solvent accessible in about one fifth of our conformers
generated in silico from the wild type native structure 1qlp,
indicating that transient solvent accessibility may be feasible in
solution in the absence of mutations. Site I is therefore a potential
ligand target site with some characteristics suggesting that ligand
binding might induce local, stabilising conformational change.
Support for this idea comes from mutagenesis studies that showed
13 mutations in the region of the I site (e.g. the space-filling
mutation His269Tyr) increased stability, while preserving inhib-
itory function [22]. Thymol and menthol are both small,
hydrophobic natural products that showed high complementarity
to the I site, and are considered safe for use in the pharmaceutical
industry. Following induced fit docking they achieved scores
comparable to the score for the CG compound discovered in
earlier studies. Some thymol derivatives achieved even better
results, although the effect of their binding could be destabilizing,
as suggested by our preliminary ThermoFluor experiments.
The channel of interconnecting sites B,C and E is also
potentially interesting as the druggability scores for these pockets
are persistently high, and some of our best docking scores are
results of docking ligands to these sites. However, the obvious
caveat of docking to this site is that many of the ligands will
interact with the RCL loop, thus potentially interfering with
A1AT’s antiprotease function. Indeed, mutation experiments have
shown that the sequence between Arg196 to Glu279 can carry 9
mutations that increase the stability of the A1AT, but in several
cases also decrease functional activity [38]. Some of the other sites
explored in our study may be more promising in terms of their
position on the surface and their lower potential to affect
inhibitory function.
There are obvious caveats in the approach presented here. The
conformers generated using CONCOORD may be artificially
produced but appeared realistic when assessed for geometry and
packing by the structure validation server PROSESS [25].
Moreover, the range of cavity characteristics observed was
consistent with the variation between crystal structures. Although
the conformational space of the protein is unlikely to be fully
explored using CONCOORD, this technique did identify
interesting pocket variations. In future work we plan to use the
program tCONCOORD, considered better for exploration of
larger variations in molecular structure [13]. The definition of
pockets on the protein surface can vary significantly between
programs, thus results presented here are specific to SiteMap
predictions. Similarly the calculation of pocket volume and other
properties are very much dependent on the definition of pocket
boundaries, which varies widely across different software. Calcu-
lations of druggability are empirical, based upon previous
correlations of scoring function predictions with in vitro observa-
tions of drug-like ligand binding. They do not guarantee in vitro
binding affinity in a new system but provide a reasonable starting
point for docking studies in silico and in vitro. Finally, our docking
calculations are subject to many approximations. They should
therefore be considered as a screening tool, based upon goodness
of fit of certain ligands against each site, to enrich true positive hits
among the ligand rankings.
In summary, we have presented a promising strategy that
utilizes multiple protein conformer structures to identify both
persistent and transiently druggable surface pockets. We have
applied this approach to A1AT, whose conformational flexibility
suggests that the usual one conformer/one pocket approach to
screening is likely to be inadequate. We have found that pockets on
the surface of A1AT show considerable variability across
conformers, and we have also identified a new transient pocket
with druggability potential. Some of our docking hits to this and
other sites are at least as good or better than a previously identified
promising lead. Finally, an unusually high proportion of a limited
set of our in silico hits targeted at the I site and assayed by
ThermoFluor alter the melting temperature of A1AT. These data
are consistent with an in vitro interaction and indicate that further
experiments are warranted to pursue these ligands and I site
targeting.
Materials and Methods
Selection of a1-antitrypsin Crystal Structures
A1AT structures were retrieved from the PDB using the SAS
tool available in PDBsum [40]. The amino acid sequence of the
structure with PDB id 1qlp was used to search the PDB, and all
sequences with percentage sequence identity higher than 97%
were kept (this very high cut-off was used as we were only
interested in sequences that did not deviate significantly from the
wild type A1AT). Among identical sequences representing
identical states, the highest resolution available was kept.
Structures with cleaved chains, where the break in the chain was
not in the RCL were removed. Our final dataset (summarised in
Table 1) comprised structures that sampled different features, such
as the stressed and relaxed forms, point mutations, and ligands
that induce stability. More specifically, there are six native stressed
and two relaxed A1AT structures, all with resolution better than or
equal to 2.6 A˚. The six native stressed structures can be separated
into two groups. The first group comprises PDB entries 1qlp [30],
2qug [41]and 3cwm [41], which have no mutations and share
Table 3. Shifts in melting temperature of A1AT in the presence of selected small molecule ligands (ThermoFluor assay).
Molecule Name DrugBank ID
Average Thermal Shift in 6C
(p-value) Predicted site of binding
Best Glide SP score
after IFD (kcal/mol)
Thymol DB02513 21.66 (0.0089) I 27.8
4-Nitrocatechol DB03407 1.92 (0.0002) I 26.9
2,6-Diisopropylphenol DB00818 21.21 (0.0021) I 28.3
The quoted p-values are the result of a Welch two-sample t-test (performed using the R statistical software) testing the null hypothesis that the difference in the mean
values of the distribution of the thermal shift values for DMSO and the distribution of the thermal shift values observed for each ligand is zero. The null hypothesis was
rejected for p-values ,0.01.
doi:10.1371/journal.pone.0036612.t003
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nearly 100% sequence similarity (except for minor variations in
the length of the C- and/or N-terminus). A partially stabilising
ligand, citrate, is present in 3cwm. The second group comprises
1hp7 [42], 1oph [43] and 3drm [32], all representing the native
stressed fold but with partially stabilising mutations in the
sequence. Finally, of the two relaxed structures, one is an
uncleaved kinetic trap of A1AT (1iz2 [37]) with ten mutations,
and the other is a cleaved form, with no mutations in its sequence,
and co-crystallised with the substrate (1ezx [19]).
Identification of Surface Pockets and Calculation of their
Properties
One protein chain from each crystal structure in our dataset was
prepared using the Protein Preparation Wizard protocol available
in the Schro¨dinger suite (Maestro package version 9.0 from
Schro¨dinger, LLC). Ligands, waters and other co-crystallised
agents were deleted and hydrogen atoms were added. The
protassign script was used to optimise intramolecular contacts.
The impref script was used to perform a restrained minimisation
of the protein, with a maximum root mean square deviation
(RMSD) of 0.30 A˚.
All structures were superimposed on the native wild type protein
(1qlp) using the structalign utility from Schro¨dinger. The site
recognition software SiteMap 2.3 (Maestro package version 9.0
from Schro¨dinger, LLC) was run on all 8 crystal structures to
identify the top 10 ranked potential ligand-binding sites. SiteMap
uses an algorithm analogous to the Goodford’s GRID algorithm
[44], which uses interaction energies between the protein and grid
probes to locate energetically favourable sites. Sites were kept if
they comprised at least 15 site points. A restrictive hydrophobicity
definition, a standard grid (1.0 A˚) and the OPLS2005 force field
were used (default settings in SiteMap 2.3).
The following physicochemical properties of the sites were
calculated by the SiteMap program: size, volume, degree of
enclosure/exposure, degree of contact, hydrophobic/-philic char-
acter, hydrophobic/-philic balance and hydrogen-bonding possi-
bilities (acceptors/donors). In addition, SiteMap calculates two
scores for each site. The SiteScore is defined as:
SiteScore~0:0733
ﬃﬃﬃ
n
p
z0:6688e{0:20p
where
n = the number of site points (capped at 100),
e = enclosure,
p = hydrophilicity of the site (capped at 1.0).
The druggability score, Dscore, is defined as:
Dscore~0:094
ﬃﬃﬃ
n
p
z0:60e{0:324p
where n, e and p are defined as above, except that p is uncapped in
this case. The developers of SiteMap suggest that a cut-off in the
SiteScore of 0.80 can be used to differentiate between drug-
binding and non-drug-binding sites, with scores higher than 1.0
being indicative of highly promising sites [45]. The Dscore can
help to distinguish between undruggable and druggable sites, by
penalising highly hydrophilic sites, as ligands binding to such sites
would be very polar, and would be quickly eliminated by the
organism. This does not mean that the site cannot bind any
ligands, but that it would be difficult to find high affinity drug-like
ligands for such a site [2].
Nine sites were identified in our dataset of crystal structures of
A1AT. These sites were labelled A to I. The geometric centre of
each site as seen in the native wild type protein (1qlp), or, in the
case of the I site, as seen in the structures bearing the Ala70 to Gly
mutation (1oph, 1iz2 and 1hp7), was calculated and it was used to
identify sites in all other crystal structures and computationally
produced conformers. This was done as follows: If the geometric
centre of a site k was within 3.75 A˚ of the geometric centre of any
site s (where s M {A,B,C,D,E,F,G,H,I}) then site k was assigned the
letter of the site s (i.e. the two sites were thought to coincide). This
cut-off is strict and it was chosen after manual inspection of several
cases where sites were very close to each other, but where it was
still possible to discriminate between them. Sites C and E overlap
in many conformers and in these cases they were assigned the label
‘‘C_E’’. If the calculated distances for a new site were between
3.75 and 10 A˚, the sites were inspected and assigned manually. If
all distances were above 10 A˚, the site was categorised as being
new. Inspection of all ‘‘new’’ sites found in conformers of 1qlp led
to approximately half of these sites being reassigned to one of the
original nine sites (A to I). The remaining unassigned sites included
mostly low-scoring sites, which were ignored in the present
analysis.
Generation of Protein Conformers Using CONCOORD
CONCOORD 2.0 [24] was used to produce alternative
conformations for the native wild type proteins (1qlp and 2qug).
The input structures were prepared with Schro¨dinger’s Protein
PreparationWizard, as detailed above. CONCOORD builds a
library of distance constraints based on the observed interatomic
distances in the original structure. Interactions deemed to be
stronger are given tighter constraints. The program then produces
randomly a large number of potential conformations, and attempts
to correct structures with atom-pair distances falling outside the
allowed regions. We allowed 1000 iterations of the correction
algorithm per structure, and rejected structures whose interatomic
distances violated the original distances by more than 3nm in total.
We set CONCOORD to an output of 100 novel conformations
for the native wild type proteins (1qlp and 2qug), which fulfilled
the distance constraints. The maximum RMSD from the original
structure was 2.96 A˚. We have also performed a CONCOORD
run that produced 5000 conformers based on the 1qlp structure.
These were only used for comparison to our more limited 100
runs. All computationally produced conformers were superim-
posed on the native wild type (1qlp) using the structalign program.
We have evaluated the quality of the CONCOORD conform-
ers using the PROSESS server [46] available at http://prosess.ca.
Table S1 contains a summary of these results.
Automated Assessment and Visualisation of Surface
Pocket Variability
For each of the 100 CONCOORD conformers potential
druggable sites were identified using SiteMap 2.3, as detailed
previously. The SiteMap output files were then merged into single
PDB files containing all predicted site sphere coordinates and were
used as input to our in-house pocket variability visualisation method
Provar. The Provar method is explained briefly here: For each
conformation, residues within 3.75A˚ of any SiteMap sphere were
considered as being pocket-lining and assigned a score of 1, all other
residues were assigned a score of 0. These scores were summed
across all conformations and divided by the number of conformers
(100) to assign each residue a probability value representing the
likelihood that it borders a predicted site. These values were written
to the B-factor column of the PDB file (1qlp), and results were
displayed using Chimera. Residue atoms and ribbons were rendered
on a continuous colour scale from white (low probability set to the
value of the first quartile of the distribution) to red (high probability
set to the value of the third quartile).
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Docking
Each of the nine sites (A to I) was used as a target for docking
small molecules. For each site, the CONCOORD conformer that
was selected to dock to was the one with the highest volume
among the ones with the top five SiteScores as predicted by
SiteMap. This selection was justified on the grounds that the
highest SiteScore was not always associated with the largest cavity,
but in rigid receptor docking a larger cavity, which allows more
room for ligands to bind can potentially make up for the lack of
side-chain flexibility during docking. Receptor grids were calcu-
lated with Glide (Maestro package version 9.0 from Schro¨dinger,
LLC), keeping default settings. The grid box was centred on the
calculated geometric mean of the particular site. The box side
lengths were set to the maximum value (14 A˚).
All ligand libraries used in this study were prepared using
LigPrep (Maestro package version 9.0 from Schro¨dinger, LLC).
The preparation involved the generation of up to 32 stereoisomers
(where these were not defined), tautomers, and protonation states
corresponding to a pH of 762 (using epik), as well as an energy
minimisation of the 3D structure using the OPLS2005 force field.
The DrugBank 3.0 [47,48] library comprised 5897 entries after
filtering to remove entries larger than 500 Daltons. Following
LigPrep preparation, this library consisted of 12115 small
molecules. The library referred to as ‘‘ZINC fragments’’ is a
representative library of fragments, based on the 3632 ZINC
‘‘clean fragments’’ subset clustered at the 60% Tanimoto similarity
(downloaded from ZINC on the 05/06/2011). The clean
fragments dataset obeyed the following criteria: xlogP,= 2.5,
molecular weight ,= 250 Daltons and number of rotatable bonds
,= 5. Following LigPrep preparation, this library contained 5324
small molecules. Finally, a small subset of the PubChem library
(1326 ligands related to thymol and extracted from PubChem,
using the ‘‘Similar Compounds Search’’ on the web entry for
thymol) was also prepared using LigPrep.
Glide with standard precision (SP) scoring was used for docking.
Epik 2.0 state penalties were used in the final scoring. The highest
scoring pose per ligand was kept and post-docking minimisation
was switched on.
Induced fit docking. A small number of molecules were
selected for induced fit docking (IFD). All these molecules had
shown promising Glide SP scores in preliminary docking trials, but
some had poor scores following the inclusion of a protein
preparation step. This suggested that IFD might be able to restore
or even improve on the original scores, as it allows the protein side
chains to optimise their position in the presence of the ligand. The
IFD protocol (Maestro package version 9.0 from Schro¨dinger,
LLC) available within the Schro¨dinger suite was employed [49].
Briefly, this protocol involves docking the ligand using a softened
potential, and refining selected docked poses using Prime side-
chain prediction and minimisation [49]. The refined protein
conformations are then used for the final Glide docking step,
where ligands are redocked, keeping the protein rigid. Default
values were used for all Glide and Prime parameters. As the
protein was prepared in advance no additional refinement was
performed at this stage. For the initial Glide docking both the
receptor and ligand van der Waals scaling were set to 0.50. Up to
20 poses were kept. The Prime induced fit step refined residues
within 5.0 A˚ of the ligand poses by optimising their side chains. In
the final step, the ligand poses were redocked using Glide SP into
structures within 30.0 kcal.mol21 of the top 20 structures.
We applied the IFD protocol to a small selection of ligands
docked in the I and C sites. This procedure was also applied to
dock the CG compound [34] to the A site in the native wild type
A1AT (1qlp).
Figures
All figures depicting A1AT, except Figure 8, were created using
the UCSF Chimera [50] package from the Resource for
Biocomputing, Visualization, and Informatics at the University
of California, San Francisco. Figure 8 was created using Maestro.
The small molecule 2-D diagrams of Figure 7 were created using
the CACTVS editor csed [51]. Plots in Figures 3B-F and 6 were
created using the statistical software R (available at http://cran.r-
project.org/doc/FAQ/R-FAQ.html).
ThermoFluor Studies
The ThermoFluor (thermal shift) assay was performed using the
iQ5 Real Time detection System (Bio-Rad – PCR Machine).
Protein unfolding was monitored by measuring the fluorescence of
the solvatochromic fluorescent dye SYPRO Orange, signalling
unfolding of the protein. The compounds to be screened were
dissolved in 100% dimethyl sulfoxide (DMSO) to give a stock
solution of 20 mM. The assay was performed in 96- well plates,
each well totalling a volume of 25 mL. Every assay had a final
concentration of 1 mg.mL21 of A1AT, 1 mM of compound giving
a final DMSO concentration of 5%, to which 1 mL SYPRO
Orange (1:200 dilution) was added. Furthermore, the influence of
DMSO and A1AT concentration on the thermal shift were
analysed. The DMSO concentration was varied to 5%, 10% and
15% and the concentration of A1AT from 1 mg.mL21 to
5 mg.mL21. Each trial was repeated 6 times (except the
5 mg.mL21 concentration of A1AT, n = 2). The starting temper-
ature for each run was 10uC increasing to 95uC in 0.5uC steps.
Supporting Information
Figure S1 Exploration of conformational space of A1AT
using CONCOORD. CONCOORD-generated conformers
from a native wild type A1AT structure ((PDB: 1qlp). (A) All
100 conformers used to analyse druggability of sites and their
occurrence. (B) The 7 structures used for docking to sites A–I;
colours for conformers are: white (site G), magenta (sites E and F),
cyan (site I), yellow (sites A and C), red (site B), blue (site H), green
(site D). (C) Three selected conformers depicting the extent to
which structural variation was simulated.
(TIF)
Figure S2 A channel of interconnecting pockets on the
surface of A1AT. (A) A channel of interconnecting surface
pockets (blue spheres) defined by the RCL at the top and the H-
helix at the bottom can be seen in several in silico produced A1AT
conformers. (B) This channel is split up into separate sites in most
conformers: B (cyan), E (fuchsia), I (yellow). These subsites
themselves occasionally overlap as in the case shown here, e.g.
site E can ‘‘spill into’’ the spaces usually occupied by sites I and B.
(TIF)
Figure S3 Site specificity of high-scoring fragment
molecules. Red diamonds represent the docking scores for the
top 5 scoring fragments for each of the sites A, BCE, D, FH, G,
and I. The boxplots summarise the corresponding (merged)
distributions of docking scores for the same five fragments docked
to all other sites.
(TIF)
Figure S4 Thermal shift and melting temperature
assays for A1AT incubated with selected ligands.
Fluorescence-based (Thermofluor) thermal shift assay curves for
A1AT incubated with small molecule ligands. Only ligands with
significant thermal shifts are shown. Representative curves
obtained in the presence of these ligands (solubilised in DMSO,
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final concentration 5% (v/v)) are shown in plots A to D (control
with 5% DMSO in grey, data from incubation with ligands in red).
The mean DTm is shown for A1AT incubated with each ligand:
(A) 5% DMSO control, (B) 4-nitrocatechol, (C) 2,6-diisopropyl-
phenol, (D) thymol. (E) Mean melting temperatures and standard
deviations for A1AT incubated with these three ligands (red) or
5% DMSO control (grey).
(TIF)
Table S1 Overall quality results for crystal structures
and in silico conformers of A1AT selected for docking
assessed by the PROSESS server (http://prossess.ca).
(DOC)
Table S2 Results for top-ranking fragments against
each of the sites A–I on A1AT. The ZINC molecule
identification codes and Glide SP docking score (within brackets,
in kcal/mol) for each of the five top-ranking fragments docked to
sites on A1AT are listed. Results for sites B, C, E and F, H are
merged.
(DOC)
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